STEADY-PD

The Parkinson Study Group (PSG) is conducting a study of the research medication isradipine CR in persons who have early  Parkinson disease (PD). Isradipine CR is a medication that is approved for the treatment of high blood pressure by the Food and Drug Administration (FDA), but not for the treatment of PD. STEADY-PD is designed to determine general safety, tolerability and pilot data on the potential effective dose of isradipine CR on slowing the progression of PD. Approximately 18 research centers across North America (including Rush) will enroll up to 100 subjects (at least 5 at Rush). Subject participation is for up to 56 weeks.  Eligible subjects will be randomized to one of three doses of active study drug or to placebo (an inactive pill that looks like the study drug). Subjects will be required for 12 study visits to evaluate general health, mood, movement ability to tolerate the study drug. This study is under a research grant award from the Michael J. Fox Foundation (MJFF) and the Northwestern Dixon Foundation.

You may be eligible to participate in this study if you:

• Have a diagnosis of PD of less than 3 years
• Are over 30 years old at the time of diagnosis
• Are able to provide written informed consent
• Are able to take oral medication and willing to comply with study-specific procedures
• Are not taking dopaminergic therapy or projected to require therapy
• Are not pregnant, lactating or intending to become pregnant

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via e-mail, please include the title of the study in your message.